Key Points
- Director John Higuchi purchased 9,037 Lipocine shares at an average price of $2.15, investing $19,429.55 and increasing his direct ownership by 4.18% to 225,395 shares.
- Lipocine shares opened at $2.07, down 5.9%, with a $17.06 million market capitalization. The company reported a quarterly loss of $0.32 per share, though it exceeded analysts’ loss estimate.
- Analyst sentiment is mixed, resulting in a consensus “Hold” rating and a $4.00 target price; institutional investors own 9.11% of the company.
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi purchased 9,037 shares of Lipocine stock in a transaction dated Tuesday, September 29th. The stock was bought at an average price of $2.15 per share, with a total value of $19,429.55. Following the completion of the purchase, the director directly owned 225,395 shares of the company's stock, valued at approximately $484,599.25. This trade represents a 4.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Lipocine Stock Down 5.9%
Shares of Lipocine stock opened at $2.07 on Friday. The company has a market cap of $17.06 million, a price-to-earnings ratio of -1.16 and a beta of 0.40. The company's 50 day moving average is $2.17 and its 200 day moving average is $2.73. Lipocine Inc. has a twelve month low of $1.81 and a twelve month high of $12.37.
Lipocine (NASDAQ:LPCN - Get Free Report) last issued its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.21 million. Sell-side analysts expect that Lipocine Inc. will post -1.54 EPS for the current fiscal year.
Institutional Investors Weigh In On Lipocine
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Eversept Partners LP purchased a new position in shares of Lipocine in the first quarter valued at about $2,357,000. AIGH Capital Management LLC purchased a new stake in shares of Lipocine during the first quarter worth about $1,598,000. Stempoint Capital LP purchased a new stake in shares of Lipocine during the first quarter worth about $1,282,000. Seven Fleet Capital Management LP bought a new stake in Lipocine during the 1st quarter valued at approximately $998,000. Finally, Persistent Asset Partners Ltd bought a new stake in Lipocine during the 4th quarter valued at approximately $567,000. 9.11% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on LPCN. HC Wainwright reissued a "neutral" rating and set a $4.00 price objective on shares of Lipocine in a research report on Monday, September 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Lipocine in a research report on Tuesday, September 22nd. Weiss Ratings raised Lipocine from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 24th. Finally, Wall Street Zen raised Lipocine from a "sell" rating to a "hold" rating in a research note on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $4.00.
View Our Latest Stock Report on Lipocine
Lipocine Company Profile
(
Get Free Report)
Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip'ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.
Lipocine's lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
